CPRX Financial Facts
Total operating costs and expenses: 3.91MResearch and development: 2.49M
See Full Income Statement
Total current assets: 45.06M
Accounts payable: 1.06M
See Full Balance Sheet
Catalyst Pharmaceutical Partners Inc. (CPRX) Earnings
|
Expand Research on CPRX
| Next EPS Date | 5/7/24 | EPS Growth Rate | -46.3% |
|---|---|---|---|
| Average EPS % Beat Rate | +126.3% | Revenue Growth Rate | +16.4% |
| Average % Move 1-Wk after EPS | -1.6% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2/28/24 | Q423 | $0.53 | $0.27 | +$0.26 | $110.57M | $106.13M | N/A |  | | Details | |
| 11/8/23 | Q323 | $0.49 | -$0.29 | +$0.78 | $102.7M | $100.37M | = | | | Details | |
| 8/9/23 | Q223 | $0.53 | $0.25 | +$0.28 | $99.5M | $92.73M | = | | | Details | |
| 5/10/23 | Q123 | $0.41 | $0.32 | +$0.09 | $85.4M | $81.62M | = | | | Details | |
| 3/15/23 | Q422 | $0.31 | $0.20 | +$0.11 | $60.76M | $56.85M | = | | | Details | |
| 11/9/22 | Q322 | $0.26 | $0.18 | +$0.08 | $57.2M | $53.62M | = | | | Details | |
| 8/9/21 |  |
Q221 | $0.17 | $0.09 | +$0.08 | $36.4M | $31.51M | N/A | | | Details |
| 8/9/22 | Q222 | $0.11 | $0.17 | -$0.06 | $33.64M | $49.21M | = | | | Details |
